A detailed history of Daiwa Securities Group Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 283 shares of BEAM stock, worth $7,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares
283
Previous 283 -0.0%
Holding current value
$7,445
Previous $7,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$36.73 - $51.6 $771 - $1,083
21 Added 8.02%
283 $11,000
Q2 2022

Aug 09, 2022

BUY
$29.86 - $62.36 $1,881 - $3,928
63 Added 31.66%
262 $10,000
Q4 2021

Feb 03, 2022

SELL
$68.02 - $99.06 $1,904 - $2,773
-28 Reduced 12.33%
199 $16,000
Q3 2021

Nov 05, 2021

BUY
$84.37 - $133.6 $9,449 - $14,963
112 Added 97.39%
227 $20,000
Q1 2021

May 03, 2021

BUY
$71.28 - $120.75 $427 - $724
6 Added 5.5%
115 $9,000
Q4 2020

Feb 04, 2021

BUY
$22.24 - $95.63 $2,424 - $10,423
109 New
109 $9,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.85B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.